On September 10, 2025, Revolution Medicines, Inc. reported clinical data for its drug daraxonrasib in treating metastatic RAS-mutant pancreatic cancer, noting a 35% objective response rate and a median overall survival of 13.1 months for patients with RAS G12X mutations as of June 30, 2025. The filing highlights treatment-related adverse events occurred in 96% of evaluated patients, with rash being the most common side effect.